BRPI0812924A2 - Imunocitocinas para o tratamento de câncer em combinação com agentes quimioterapêuticos - Google Patents
Imunocitocinas para o tratamento de câncer em combinação com agentes quimioterapêuticosInfo
- Publication number
- BRPI0812924A2 BRPI0812924A2 BRPI0812924-0A2A BRPI0812924A BRPI0812924A2 BR PI0812924 A2 BRPI0812924 A2 BR PI0812924A2 BR PI0812924 A BRPI0812924 A BR PI0812924A BR PI0812924 A2 BRPI0812924 A2 BR PI0812924A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunocytocins
- cancer
- treatment
- combination
- chemotherapeutic agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94676107P | 2007-06-28 | 2007-06-28 | |
PCT/IB2008/002310 WO2009001219A2 (en) | 2007-06-28 | 2008-06-25 | Immunocytokines for cancer treatment in combination with chemotherapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0812924A2 true BRPI0812924A2 (pt) | 2014-12-09 |
Family
ID=40029217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0812924-0A2A BRPI0812924A2 (pt) | 2007-06-28 | 2008-06-25 | Imunocitocinas para o tratamento de câncer em combinação com agentes quimioterapêuticos |
Country Status (11)
Country | Link |
---|---|
US (3) | US20100215615A1 (pt) |
EP (1) | EP2162156A2 (pt) |
JP (1) | JP2010531349A (pt) |
KR (1) | KR20100040884A (pt) |
CN (1) | CN101687049B (pt) |
AU (1) | AU2008269441B2 (pt) |
BR (1) | BRPI0812924A2 (pt) |
CA (1) | CA2692263C (pt) |
EA (1) | EA018746B1 (pt) |
MX (1) | MX2009013752A (pt) |
WO (1) | WO2009001219A2 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120107270A1 (en) * | 2009-06-30 | 2012-05-03 | Manuela Kaspar | Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer |
JP6241912B2 (ja) * | 2012-04-27 | 2017-12-06 | 国立研究開発法人量子科学技術研究開発機構 | 核医学診断装置の制御方法、核医学診断装置、および診断剤キット |
CN102977214B (zh) * | 2012-09-29 | 2014-03-12 | 重庆原伦生物科技有限公司 | 用于耐甲氧西林金黄色葡萄球菌(mrsa)疫苗的重组蛋白hf2及制备方法和应用 |
EP2988784A1 (en) | 2013-04-25 | 2016-03-02 | Philogen S.p.A. | Antibody-drug conjugates |
US11883503B2 (en) | 2017-09-25 | 2024-01-30 | Dingfu Biotarget Co., Ltd. | Methods and compositions for cancer treatment |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7172901A (en) * | 2000-06-29 | 2002-01-14 | Lexigen Pharm Corp | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
GB0209896D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
EP2157102A1 (en) * | 2004-11-09 | 2010-02-24 | Philogen S.p.A. | Antibodies against tenascin-C |
US20120107270A1 (en) * | 2009-06-30 | 2012-05-03 | Manuela Kaspar | Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer |
-
2008
- 2008-06-25 MX MX2009013752A patent/MX2009013752A/es not_active Application Discontinuation
- 2008-06-25 JP JP2010514182A patent/JP2010531349A/ja not_active Withdrawn
- 2008-06-25 KR KR1020107001867A patent/KR20100040884A/ko not_active Application Discontinuation
- 2008-06-25 CA CA2692263A patent/CA2692263C/en not_active Expired - Fee Related
- 2008-06-25 AU AU2008269441A patent/AU2008269441B2/en not_active Ceased
- 2008-06-25 EP EP08789128A patent/EP2162156A2/en not_active Withdrawn
- 2008-06-25 US US12/452,264 patent/US20100215615A1/en not_active Abandoned
- 2008-06-25 BR BRPI0812924-0A2A patent/BRPI0812924A2/pt not_active IP Right Cessation
- 2008-06-25 EA EA200971103A patent/EA018746B1/ru not_active IP Right Cessation
- 2008-06-25 WO PCT/IB2008/002310 patent/WO2009001219A2/en active Application Filing
- 2008-06-25 CN CN2008800219308A patent/CN101687049B/zh not_active Expired - Fee Related
-
2012
- 2012-11-16 US US13/679,374 patent/US20130108581A1/en not_active Abandoned
-
2014
- 2014-08-12 US US14/457,522 patent/US20150010498A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009001219A9 (en) | 2010-02-11 |
WO2009001219A3 (en) | 2009-09-03 |
US20100215615A1 (en) | 2010-08-26 |
CA2692263A1 (en) | 2008-12-31 |
EA018746B1 (ru) | 2013-10-30 |
US20150010498A1 (en) | 2015-01-08 |
CN101687049B (zh) | 2013-01-23 |
EP2162156A2 (en) | 2010-03-17 |
MX2009013752A (es) | 2010-02-01 |
AU2008269441A1 (en) | 2008-12-31 |
JP2010531349A (ja) | 2010-09-24 |
CA2692263C (en) | 2015-11-24 |
EA200971103A1 (ru) | 2010-08-30 |
WO2009001219A2 (en) | 2008-12-31 |
AU2008269441B2 (en) | 2013-10-10 |
KR20100040884A (ko) | 2010-04-21 |
US20130108581A1 (en) | 2013-05-02 |
CN101687049A (zh) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0817293A2 (pt) | Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese | |
IL201211A (en) | K3 ip-alpha quinoxaline inhibitors for use in combination with chemotherapeutic agents for use in the treatment of cancer | |
BRPI0816209A2 (pt) | Artigos absorventes descartáveis do tipo para vestir com subsistemas de ancoramento. | |
PT2601962T (pt) | Regime de dosagem de lag-3 para utilização no tratamento de cancro | |
BRPI0921321A2 (pt) | métodos para o tratamento de indwcções e tumores | |
IL219992A0 (en) | Combination therapy for treating cancer and dianostic assays for use therein | |
IL195731A0 (en) | Pyrimidine derivatives useful in the treatment of cancer | |
BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
ZA200905159B (en) | Combination of LBH589 with other therapeutic agents for treating cancer | |
IL186662A0 (en) | Combination cancer therapy with | |
PT2101731T (pt) | Endoxifeno para utilização no tratamento de cancro | |
GB0714384D0 (en) | theraputic agents | |
BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
HK1215683A1 (zh) | 抗葉酸藥在癌症治療中的聯合應用 | |
BRPI0906444A2 (pt) | Compostos de 4-piridinona e seu uso para câncer | |
BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. | |
DK2147122T3 (da) | Enzymatisk kræftbehandling | |
BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer | |
BRPI0810207A2 (pt) | Métodos e composições para o tratamento de câncer | |
IL199911A0 (en) | 3-cinnolinecarboxamide derivatives and their use for treating cancer | |
BRPI0812924A2 (pt) | Imunocitocinas para o tratamento de câncer em combinação com agentes quimioterapêuticos | |
HK1151971A1 (en) | Compounds for use in the treatment of cancer | |
BRPI0918508A2 (pt) | orto-aminoanilidas para o tratamento de câncer | |
BRPI0821100A2 (pt) | composições e métodos para o tratamento de câncer de bexiga |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/337 (2006.01), A61K 31/704 (2006.01), A61K |